The downgrade from Strong Buy to Outperform may initially seem negative, but the increase in price target from $26 to $29 suggests that Raymond James still sees growth potential in PPBI, albeit with a more conservative outlook. This mixed signal could lead to a neutral short-term impact on the stock as investors digest both the downgrade and the raised price target.